REGENERON PHARMACEUTICALS, INC. (REGN)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | 3,675,600 | 3,028,700 | 3,720,700 | 3,547,100 |
| Selling, general, and administrative | 634,200 | 633,000 | 714,400 | 758,800 |
| Research and development | 1,421,700 | 1,327,400 | 1,271,500 | 1,200,000 |
| Other operating expense (income), net | - | - | -8,000 | -14,600 |
| Cost of goods sold, collaboration and contract manufacturing-Product | 275,600 | 265,500 | 262,300 | 257,800 |
| Cost of goods sold, collaboration and contract manufacturing-Collaborationand Contract Manufacturing | 254,600 | 198,800 | 228,800 | 222,400 |
| Acquired in-process research and development | 10,000 | 12,300 | 56,200 | 23,900 |
| Total expenses | 2,596,100 | 2,437,000 | 2,541,200 | 2,477,500 |
| Income from operations | 1,079,500 | 591,700 | 1,179,500 | 1,069,600 |
| Other income (expense), net | 442,800 | 322,000 | 327,300 | 573,300 |
| Interest expense | 3,600 | 8,700 | 13,800 | 14,800 |
| Total other income (expense) | 439,200 | 313,300 | 313,500 | 558,500 |
| Income before income taxes | 1,518,700 | 905,000 | 1,493,000 | 1,628,100 |
| Income tax expense | 127,100 | 96,300 | 152,400 | 195,800 |
| Net income | 1,391,600 | 808,700 | 1,340,600 | 1,432,300 |
| Gain (loss) on foreign currency translation | 1,300 | -1,100 | 1,900 | - |
| Unrealized gain on debt securities | 22,100 | 38,100 | 128,200 | 7,900 |
| Loss on foreign currency translation | - | - | - | -600 |
| Comprehensive income | 1,415,000 | 845,700 | 1,470,700 | 1,439,600 |
| Net income per share - basic (in dollars per share) | 13.24 | 7.58 | 12.4 | 13.25 |
| Net income per share - diluted (in dollars per share) | 12.81 | 7.27 | 11.54 | 12.41 |
| Weighted average shares outstanding - basic (in shares) | 105,100,000 | 106,700,000 | 108,100,000 | 108,100,000 |
| Weighted average shares outstanding - diluted (in shares) | 108,600,000 | 111,200,000 | 116,200,000 | 115,400,000 |